source
- Q32 Bio’s alopecia drug bempikibart meets Phase 2 goal, driving shares up 80%Q32 Bio reported that its experimental alopecia areata therapy, bempikibart, achieved the primary endpoint in the second part of a Phase 2 trial. Two‑fifths of participants grew enough hair to cove…
- Ohio launches $30M Life Science Training Center to boost biomanufacturing workforceOhio’s JobsOhio agency and the Ohio Life Sciences Association announced a public-private training center backed by up to $30 million. The center is intended to create a statewide pipeline of operat…